Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to ...
4d
Here’s Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade
Eli Lilly and Company (NYSE:LLY) is one of the 10 Best American Stocks to Buy and Hold for the Next Decade. On May 31, 2026, ...
Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the ...
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL ...
Eli Lilly and Company (NYSE:LLY) announced positive data from its Phase 3 LIBRETTO-432 trial, showing that Retevmo significantly lowered the risk of disease recurrence or death in patients with ...
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...
Eli Lilly (LLY) said its targeted cancer therapy Retevmo significantly reduced the risk of disease recurrence or death in ...
In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Jan 22 (Reuters) - Eli Lilly and Co's stomach cancer drug ramucirumab met its primary goal of improving overall survival in a late stage-study, extending the lives of patients for more than a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results